Patients with BRCA1 or BRCA2-mutated carriers are advised to consider prophylactic bilateral mastectomy (PBM) which has been shown to reduce the incidence of breast cancer by approximately 90% [57-59]. This evidence concerns the gene BRCA2 and breast carcinoma.